Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neurosense Therapeutics Ltd. (NRSN)
NASDAQ:NRSN
RESEARCH TOOLSreports
Holding NRSN?
Track your performance easily
NRSN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.51 - $2.33
Previous Close$0.86
Volume556.47K
Average Volume (3M)195.99K
Market Cap
$17.81M
Enterprise Value$15.24M
Total Cash (Recent Filing)$2.64M
Total Debt (Recent Filing)$73.00K
Price to Earnings (P/E)―
Beta2.28
Next Earnings
Mar 19, 2025EPS Estimate
-$0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding19,470,000
10 Day Avg. Volume368,332
30 Day Avg. Volume195,987
Standard Deviation0.48
R-Squared0.02
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)-8.60
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.37
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Neurosense Therapeutics Ltd. News
PremiumCompany Announcements
NeuroSense Advances ALS Treatment with PrimeC, Boosts Financial Position
PremiumCompany Announcements
NeuroSense Therapeutics Regains Nasdaq ComplianceOwnership Overview
26.88%
Insiders
0.06% Mutual Funds
0.58% Other Institutional Investors
72.49% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
NRSN FAQ
What was Neurosense Therapeutics Ltd.’s price range in the past 12 months?
Neurosense Therapeutics Ltd. lowest stock price was $0.51 and its highest was $2.33 in the past 12 months.
What is Neurosense Therapeutics Ltd.’s market cap?
Currently, no data Available
When is Neurosense Therapeutics Ltd.’s upcoming earnings report date?
Neurosense Therapeutics Ltd.’s upcoming earnings report date is Mar 19, 2025 which is in 87 days.
How were Neurosense Therapeutics Ltd.’s earnings last quarter?
Neurosense Therapeutics Ltd. released its earnings results on Nov 27, 2024. The company reported -$0.11 earnings per share for the quarter, the consensus estimate of -$0.11 by $0.
Is Neurosense Therapeutics Ltd. overvalued?
According to Wall Street analysts Neurosense Therapeutics Ltd.’s price is currently Overvalued.
Does Neurosense Therapeutics Ltd. pay dividends?
Neurosense Therapeutics Ltd. does not currently pay dividends.
What is Neurosense Therapeutics Ltd.’s EPS estimate?
Neurosense Therapeutics Ltd.’s EPS estimate is -$0.08.
How many shares outstanding does Neurosense Therapeutics Ltd. have?
Neurosense Therapeutics Ltd. has 20,709,480 shares outstanding.
What happened to Neurosense Therapeutics Ltd.’s price movement after its last earnings report?
Neurosense Therapeutics Ltd. reported an EPS of -$0.11 in its last earnings report, expectations of -$0.11. Following the earnings report the stock price went up 3.333%.
Which hedge fund is a major shareholder of Neurosense Therapeutics Ltd.?
Among the largest hedge funds holding Neurosense Therapeutics Ltd.’s share is Woodline Partners LP. It holds Neurosense Therapeutics Ltd.’s shares valued at N/A.
---
Neurosense Therapeutics Ltd. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Hedge Fund Trend
Decreased
By 19.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
26.47%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-76.60%
Trailing 12-Months
Company Description
Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its lead product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
---
NRSN Stock 12 Month Forecast
Average Price Target
―Technical Analysis
---